Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Oral Doses of Bemnifosbuvir/Ruzasvir Fixed-dose Combination on the Single-Dose Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/ Levonorgestrel) in Healthy Adult Female Participants of Non-Childbearing Potential

Next Previous
Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Oral Doses of Bemnifosbuvir/Ruzasvir Fixed-dose Combination on the Single-Dose Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/ Levonorgestrel) in Healthy Adult Female Participants of Non-Childbearing Potential

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Atea Pharmaceuticals

Most Recent Events

  • 24 Dec 2025 awaiting for RDI editor, if NP is going to be created for Ethinyl Estradioll/Levonorgestrel (EE/LNG) , will add as and when created and completed by RDI editor, completing with main primary drug for now. Dates have some discrepancy , all planned dates are same in NCT 1 Dec 2025, have retained only planned initiation for now, pls update when correct dates are available. Indication assumed from RDI, pls update further
  • 19 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top